

ABCC11, ABCF2 and ABCG1). Finally, SNPs in *ABCB1* gene coding a prototypical anticancer drug efflux pump (rs1128503, rs2032582 and rs1045642) were estimated. The rs1128503 and rs1045642 SNPs were significantly associated with expression of ABCB1 and estrogen receptor in our previous study (Vaclavikova et al. *Pharmacogenet Genomics* 2008;18:263–273).

Conclusions: Our results revealed new candidate genes potentially causing the multidrug resistance of mammary tumour cells. Validation study on upregulated ABC transporters will be performed by absolute quantification in an independent patient cohort. The association of expression profiles with therapy outcome and disease-free survival will also be analyzed. In addition, new HRM method that seems to be rapid, accurate and low-cost as well as time-effective was developed for screening of functional *ABCB1* and analogously another ABC gene(s) SNPs. This work was supported by grants of Grant Agency of the Ministry of Health of the Czech Republic, grants no.: NS9803–3 and NS9799–4.

5031

POSTER

Breast Cancer in Young Woman in South of Morocco

M. Khouchani¹, A. Elomrani¹, A. Mharech¹, T. Morjani¹, A. Tahri¹. ¹Chu Mohammed Vi, Oncology Radiotherapy, Marrakech, Morocco

Background: The breast cancer is the first cancer of the woman in the world. it remains infrequent at the young woman. The objective of this study is to identify the epidemiological, clinicopathological and evolutionary features of breast cancer in young women at the oncology department of Mohammed VI University Hospital in Marrakech.

Materials and Methods: This retrospective study involved 154 young patients of 40 years old and less suffering from breast cancer, treated and followed up between January 2003 and December 2007.

Results: The mean age was of 35.1 years and 19 patients (12.3%) had familial history of breast cancer. Palpable tumour was found in 96.8% of cases with a clinical average size of 6 cm. Cancers were classified T1 in 17.8% of patient, T2 in 31.8%, T3 in 20.7% and 39.7% with T4. We found an invasive ductal carcinoma in 71.1% of cases, 97% were SBR grade II and III. The study of the operative specimen showed a axillary node invasion in 83 women (68.5%) and Hormone receptors were absent in more than 50% of case. The hormone therapy by tamoxifene was indicated at 53 patients associated in a castration by radiotherapy to four of them. The average length of the follow-up period was 39.6 months. We noticed that 34% of 103 women having a controlled disease at the end of treatment presented a relapse for an average time of 16.6 months. The global survival rate at 3 years was 66.1%.

Conclusion: With a high rate of relapse in our series, Prognosis appears unfavourable among young women with breast cancer in our region. Our results are consistent with those of the majority of published reports.

5032

POSTER

Clinical Outcome of Central Nervous System Metastases From Breast Cancer: Differences in Survival Depending on Systemic Treatment

H. Kim¹, S. Im², J. Park¹, S. Han², D. Oh², J. Kim³, E. Chie⁴, T. Kim², Y. Bang², S. Ha¹. ¹Seoul National University Hospital, Department of Internal Medicine, Seoul, Korea; ²Seoul National University Hospital Seoul National University College of Medicine, Department of Internal Medicine, Seoul, Korea; ³Seoul National University Bundang Hospital Seoul National University College of Medicine, Department of Internal Medicine, Seongnam, Korea; ⁴Seoul National University Hospital Seoul National University College of Medicine, Department of Radiology, Seoul, Korea

Background: Central nerve system (CNS) metastases are a feared complication of breast cancer and are associated with poor prognosis. The purpose of this study is to investigate the clinical characteristics of CNS metastases and to clarify the prognostic factors after CNS metastases in breast cancer at a single institution over a long time period.

Patients and Methods: We retrospectively reviewed the medical records of breast cancer patients diagnosed at Seoul National University Hospital from 1981 to 2009 and identified the patients who experienced CNS metastases. We collected the data including demographics, clinicopathologic characteristics, dates of diagnosis of original breast cancer and subsequent metastases, date of death and correlated the findings with the clinical outcome.

Results: Total of 400 patients were identified, 17 patients (4.3%) were diagnosed CNS metastases with primary breast cancer concurrently and 383 (95.7%) experienced CNS metastases subsequently after the diagnosis of primary breast cancer. 318 patients (79.5%) had brain parenchymal metastases only, 30 (7.5%) had leptomeningeal metastases only, and 52 (13%) had both. After the diagnosis of CNS metastasis, 170 patients (42.5%) received systemic chemotherapy (CTx) and 143

(35.8%) received CTx after whole brain radiation therapy (WBRT). The patients with good performance status (PS), initial CNS metastasis as recurrence, absence of extracranial metastases, non-visceral extracranial metastases, longer interval from the date of primary breast cancer to the date of CNS metastasis, CTx after WBRT and gamma-knife surgery (GKS) had better outcomes in univariate analyses. In multivariate analysis, good PS, systemic CTx after WBRT, GKS, and longer interval to CNS metastasis, were independent prognostic factors for overall survival after CNS metastases.

Conclusions: Our results suggest that appropriate palliative systemic therapy after WBRT or GKS, adequate palliative treatment via combined modalities are helpful for breast cancer patients, even after the detection of CNS metastases.

5033

POSTER

Re-irradiation Plus Hyperthermia for 415 Patients With Recurrent Breast Cancer in Previously Irradiated Area – the Amsterdam + Tilburg Experience

S. Oldenberg¹, V. Griesdoorn¹, Y. Kusumanto¹, R. van Os¹, S.B. Oei², J.L.M. Venselaar², J. Crezee¹, P.J. Zum Vörde Sive Vörding¹, C.C.E. Koning¹, G. Tienhoven¹. ¹Academic Medical Center, Radiation Oncology, Amsterdam, The Netherlands; ²Institute Verbeeten, Radiation Oncology, Tilburg, The Netherlands

Background: Treatment options for patients with locoregional recurrent breast cancer in previously irradiated area are limited. Four hundred and fourteen patients were treated with re-irradiation and hyperthermia (re-RT/HT) in the AMC (n = 301) and the BVI (n = 113) from January 1982 till January 2006. Response, locoregional control and toxicity were analysed as well as prognostic factors.

Patients/methods: All patients received extensive previous treatments, including surgery, chemotherapy and irradiation to a median dose of 50 Gy with or without boost. Median interval between initial treatment and re-RT-HT was 54 months (range 3–469).

The median age was 57 years at start of re-RT/HT. The estimated tumour size was >10 cm in 48% of patients, distant metastases were present in 36% and 74% had experienced 1–13 recurrence episodes, prior to the re-RT-HT. Re-RT consisted typically of 8x4 Gy, twice a week (AMC) or 12x3 Gy, four times per week, (BVI). Superficial hyperthermia was added once/twice a week using 434MHz CFMA antennas. Aim temperature: 41–43°C for one hour. Fifteen percent of patients received sequential chemotherapy and 30% sequential hormone therapy.

Results: Overall clinical response rate (cCR+cPR) was 84%. The infield 3-year local control (LC) rate was 25%. Tumour size, interval, previous recurrences and distant metastases (DM) were important prognostic factors. For patients with isolated locoregional recurrences ≤5 cm the 3-year LC rate was 47% (Table 1).

Median overall survival was 17 months. Acute ≥ grade 3 toxicity occurred in 24% of patients. The actuarial late ≥ grade 3 toxicity rate was 23% at 3 years.

Table 1

Tumour size	cCR (%)		3-y LC (%)	
	Isolated	With DM	Isolated	With DM
0–5 cm	86	54	47	22
5–10 cm	65	40	29	22
>10 cm	58	36	21	11

Discussion and Conclusion: The combination of re-irradiation and hyperthermia results in high response rates despite extensive disease. Early referral is needed to achieve long term locoregional control. Currently a randomized study of RT-HT versus RT-HT and CisDiamineDichloroPlatinum is performed to further improve results.

5034

POSTER

Baseline Characteristics, Disease Pattern and Outcome of Breast Cancer Patients With Asymptomatic Bone Metastasis

A. Munshi¹, V. Palwe¹, A. Budrukkar¹, R. Jalali¹, R. Sarin¹, S. Gupta², J. Ghosh², V. Parmar³, N. Nair³, R. Badwe³. ¹Tata Memorial Hospital, Radiation Oncology, Mumbai, India; ²Tata Memorial Hospital, Medical Oncology, Mumbai, India; ³Tata Memorial Hospital, Surgical Oncology, Mumbai, India

Background: Nearly 30–70% of all cancer patients develop bone metastasis. There is enough clinical evidence for the role of ionizing radiation in symptomatic bone metastasis. However, nearly 20% of patients

with bone metastasis do not have pain and are asymptomatic. This is the first study that assesses the pattern of disease and outcome of breast cancer patients with asymptomatic bone metastasis.

Material and Methods: We did a retrospective study of all breast cancer patients with asymptomatic bone metastasis from January 2009 to December 2010. The inclusion criteria were females with breast cancer with bone scan or PET scan positive for bone metastasis. All patients were completely asymptomatic with respect to bone metastasis. In all 70 patients were analysed. In each case the decision for treating patients with systemic therapy/radiotherapy/bisphosphonates was taken by the Joint Clinic/Radiation Oncologist at the hospital. In general radiotherapy was given only when the involved area was weight bearing areas/with gross bony involvement.

Results: Out of 70 patients, 38(54.3%) were post menopausal. 44(62.9%) patients had bone metastasis at presentation while 26(37.1%) had these at some stage of their follow up for radically treated breast cancer. 36(51.4%) patients had a single site of bone metastasis while the rest had multiple sites of involvement. 44(62.9%) patients had ER and/or PR receptor positivity. Overall, bone metastasis were detected by bone scan in 57 (87.4%), PET scan in 11 (15.7%) and CT scan 2(2.9%). There was no other site of metastasis in 47(67.1%) while the rest of the patients had other site of metastasis including liver 8(11.4%), lung 11(15.7%) or multiple 4(5.8%). Only 8(11.4%) patients received immediate RT, while delayed radiotherapy had to be given in 12(17.1%). No radiotherapy was given in 49(70%) patients till last follow up. Overall, at median follow up of 8 months, only 16(22.9%) patients became symptomatic for their bone metastasis. 75 patients received some form of systemic chemotherapy during their overall course. At last follow up 63(90%) were alive.

Conclusion: The baseline clinical and pathological features of breast cancer patients with asymptomatic bone metastasis have been presented. Patients with asymptomatic bone metastasis are a favourable subgroup. Further prospective and randomised trials would confirm our findings and establish the optimal treatment in such patients.

5035

POSTER

Quality Indicators Used to Measure Adherence to Standards of Breast Cancer Care – a Single Institutional Study From Ukraine

Y. Michailovich¹, A. Gaisenko¹. ¹National Cancer Institute in Ukraine, Research Department The Quality Management of Cancer Care Patients, Kyiv, Ukraine

Background: Data of the Ukrainian National Cancer Registry were analyzed for purpose to evaluate the quality of operable breast cancer care in a tertiary care institution. Quality Indicators has been proven to detect breast cancer at an early stage and, when followed up with appropriate diagnosis and treatment, to reduce mortality from breast cancer as well as improvement of survivorship, over time. The purpose of this systematic research was to survey the range of measures assessing the quality of breast cancer care in women and to characterize specific parameters potentially affecting their suitability for wider use in Ukraine.

Material and Methods: Quality Indicators were based on an international consensus and review of 143 Indicators that have been developed by the University of Ottawa Evidence-based Practice Center for the Agency for Healthcare Research and Quality. Twenty-six quality indicators: 5 structure-related, 16 relating to process (6 diagnosis-related and 10 treatment-related indicators) and 5 outcome-related (e.g., quality of life) were used to measure the quality of care in 1461 breast cancer patients treated from 2000 to 2005. Data were abstracted from the charts of these patients. Adherence to each indicator was based on the number of procedures performed divided by the number of patients eligible for that procedure. This research explores whether 100% adherence to a set of quality indicators applied to individuals with breast cancer is associated with better survival, and was done in Ukraine the first time. The main analysis of adherence was dichotomous (ie, 100% adherence vs. <100% adherence). The outcome measures studied were 5-year overall survival and progression-free survival, calculated using the Kaplan–Meier method. The Cox's proportional hazard regression model was used for univariate and multivariate analyses.

Results: Most patients received care that demonstrated good adherence to the quality indicators. Multivariate analysis revealed that 100% adherence to entire set of quality indicators was significantly associated with better overall survival [hazard ratio (HR): 0.46; 95% confidence interval (CI): 0.34–0.63] and progression-free survival (HR 0.51; 95% CI, 0.39–0.68). One hundred percent adherence to treatment indicators alone was also associated with statistically significant improvements in overall and progression-free survivals.

Conclusions: Our study strongly supports that 100% adherence to evidence supported quality of care indicators is associated with better survival rates for breast cancer patients and should be a priority for practitioners. Our study demonstrated that the quality of breast cancer care

in this institution was below the accepted international standards. However, this study may be used to make interventions for improvement of quality in similar institutions all over the Ukraine.

5036

POSTER

Clinical and Pathological Prognostic Characteristic of Breast Cancer Patients With Brain Metastases

K. Helis¹, E. Pluta², M. Hetnal², K. Trela¹, R. Kulik¹, D. Gabrys¹. ¹Center of Oncology Maria Skłodowska-Curie Memorial, Radiation Oncology, Gliwice, Poland; ²Center of Oncology Maria Skłodowska-Curie Memorial, Radiation Oncology, Kraków, Poland

Successful improvement in breast cancer patient's treatment leads to life prolongation. This is connected with rising incidence of brain metastases (BM) which occurs in up to one third of patients with metastatic breast cancer. The aim of this study is to analyze clinical and pathological factors in patients with BM.

This is a retrospective study of 247 breast cancer patients with brain metastases, treated with brain radiotherapy between 2005–2009 at two Cancer Centres, Gliwice, Krakow. Previously we presented data from patients treated between 2005–2007.

Patient's age at time of diagnosis ranged from 25 to 80 years, average 51 years. Patients' stages at time of cancer diagnosis were: T1–2: 38%, T3–4: 42%, N0–1: 54%, N2–3: 27%.

Majority of patients were treated primary with radical intent 81%. Most of patients underwent radical mastectomy 74% or breast conserving therapy 6%. Ductal invasive carcinoma was the predominant histology accounts for 65%. Lymph nodes metastases were present in 45% of patients with median lymph nodes ratio 17%. Tumours were ER, Pr receptor positive only in 31% and 26%, and only 13% for ER and 10% PR were highly positive. We are able to establish HER2 status in 54% of patients and in 22% HER2 was negative, and highly positive in 19%.

All patients were treated with radiotherapy, 58% underwent whole brain radiotherapy, 19% underwent metastasectomy, 36% stereotactic irradiation, in combination with WBRT 18% or alone 8%. Median time from diagnosis to BM was 2.8 years (range 0–21), to distant relapse 2.1 or local relapse 2.6. Single Bm was diagnosed in 28%, and multiple metastases in 32% of patients, remaining had 2–7 lesions.

Median time from treatment dissemination to brain relapse was 0.24 years. Median time to BM was 2.9 years. Median time to BM was longer in ER+ patients 3.8 years vs ER– patients 2.3, and PR+ patients 3.7 years vs PR– patients 2.3. A median time to BM shortened with T stage and N stage.

Advanced stages, ER–, PR–, are related to higher risk of BM. Major cause of death was brain metastases, therefore further studies are needed for early BM patients selection.

5037

POSTER

A Dosimetric Comparison of Inverse Intensity-modulated Radiotherapy and Forward Intensity-modulated Radiotherapy for Breast Cancer After Radical Mastectomy

G. Zhang¹, Y. Yin¹, J. Lu¹. ¹Shandong Cancer Hospital and Institute, Radiation Oncology Physics, Jinan, China

Background: To evaluate the dose distribution of target volume and normal tissues in forward intensity modulated radiotherapy (f-IMRT) and inverse intensity modulated radiotherapy (IMRT) planning for breast cancer after radical mastectomy.

Materials and Methods: Ten patients with breast cancer who received radical mastectomy were enrolled in this study. On each patient's CT images the supraclavicular, chest wall and internal mammary areas were delineated. fIMRT and IMRT plans were performed for each patient. The prescription dose was 50 Gy in 25 fractions. fIMRT plans for the supraclavicular and the chest wall area using 6 MV X-ray irradiation, internal mammary area with 9–12 MeV electron irradiation, according to the three regions of dose adjust the doses of cold and hot fit. IMRT plans were take supraclavicular, chest wall and internal mammary area as a whole target, using 6 MV X-ray, performing inverse optimal design. The dose distribution of target volume and normal tissues, conformal index (CI), and heterogeneous index (HI) were analyzed using the dose-volume histogram (DVH) for the two intensity modulated modes.

Results: The maximum dose of PTV in IMRT plan was lower than that of f-IMRT plan ($t = -3.23$, $P < 0.05$), the minimum dose and $V_{95\%}$ of PTV were higher than that of f-IMRT plan ($t = 4.08$, -2.69 , $P < 0.05$). About CI and HI, IMRT plan were better than f-IMRT plan ($t = -3.13$, 2.74 , $P < 0.05$). The differences of V_{10} , V_{20} , V_{25} , V_{30} and D_{mean} of ipsilateral lung were not statistically significant. However, the V_{15} of ipsilateral lung in IMRT was 4.2% less than that in f-IMRT, which was statistically significant ($t = 3.2$, $P < 0.05$). There was no significant difference in D_{mean} and V_{30} of heart, D_{mean} of contralateral lung and contralateral breast between two modes.